Our lab is focused on developing novel therapeutic strategies that target leukemia and leukemia stem cells. Using chemical and genetic approaches, our laboratory investigates targeting protein synthesis and degradation pathways in the mitochondria and cytoplasm. Mechanistic studies are coupled with preclinical evaluation to understand the biology of leukemia stem cells and highlight therapeutic strategies with potential therapeutic windows. In addition to acting as biological tools, these molecules also serve as leads for potential new treatment strategies. For example, using these approaches, we have demonstrated that acute myeloid leukemia (AML) cells and stem cells have a unique reliance on mitochondrial metabolism and have heightened sensitivity to inhibitors of mitochondrial translation. We have also demonstrated increased lysosomal mass in AML cells and increased sensitivity to lysosome disruption in this disease. To rapidly identify and test new therapeutic strategies in early proof-of-principle clinical trials, the Schimmer lab has also advanced compounds directly from the lab into Phase I clinical trials.
Aaron D Schimmer
Leukemia. 2017 Jan 23;:
Longitudinal assessment of physical and psychological function in older patients with acute myeloid leukemia (AML): A pilot study.
J Clin Oncol. 2004 Jul 15;22(14_suppl):8273
Int J Lab Hematol. 2016 Dec 25;:
A safety and schedule seeking trial of Bcl-2 inhibitor obatoclax in previously untreated older patients with acute myeloid leukemia (AML).
J Clin Oncol. 2009 May 20;27(15_suppl):3579
Nature. 2016 Dec 07;:
Characterizing the mitochondrial DNA polymerase gamma interactome by BioID identifies Ruvbl2 localizes to the mitochondria.
Mitochondrion. 2016 Nov 11;:
Oncotarget. 2016 Oct 27;:
Cancer Med. 2016 Oct 13;:
Predictive value of molecular remissions postconsolidation chemotherapy in patients with Core Binding Factor Acute Myeloid Leukemia (CBF-AML) - a single center analysis.
Hematol Oncol. 2016 Sep 6;
Senior Scientist, Princess Margaret Cancer Centre
Professor, Department of Medical Biophysics, University of Toronto
Staff Physician, Leukemia Site Group, Princess Margaret Cancer Centre